VIM and hepatocellular carcinoma: The galactosylated liposomal doxorubicin vehicle (Gal-DOX-L) and gal-doxorubicin/vimentin siRNA liposome (Gal-DOX/siRNA-L) had the correct size (<100 nm and <140 nm, each), delivered DOX and siRNA into hepatoma cells showing dose-dependent efficacy.